CORMEDIX INC. Retained Earnings
CORMEDIX INC. (CRMD) had Retained Earnings of -$111.99 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$111.99M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$137.97M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$176.57M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$190.60M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$111.99M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$137.97M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | -$176.57M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$190.60M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$299.16M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$318.99M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | -$339.63M 10-K · filed 2026-03-05 | -$339.63M 10-K · filed 2025-03-25 |
| 2024-09-30 | -$353.09M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | -$350.32M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | -$336.17M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | -$321.70M 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$306.95M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | -$297.20M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$285.93M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | -$275.36M 10-K · filed 2024-03-12 | |
| 2022-09-30 | -$267.15M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$260.30M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$252.69M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$245.66M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$237.87M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$229.30M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | -$224.67M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$217.45M 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$211.36M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | -$204.76M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | -$200.98M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | -$195.42M 10-K · filed 2021-03-30 | |
| 2019-09-30 | -$190.12M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$184.85M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$184.16M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | -$178.99M 10-K · filed 2020-03-16 | |
| 2018-09-30 | -$181.14M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$170.90M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | -$162.34M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$152.17M 10-K · filed 2019-05-29 | |
| 2017-09-30 | -$141.86M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | -$131.91M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | -$126.76M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$119.16M 10-K · filed 2018-03-19 | |
| 2016-09-30 | -$112.64M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | -$103.51M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | -$98.62M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | -$94.39M 10-K · filed 2017-03-16 | |
| 2015-09-30 | -$90.53M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | -$85.84M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | -$81.70M 10-Q · filed 2015-05-07 | |
| 2014-12-31 | -$76.20M 10-K · filed 2016-03-15 | |
| 2014-09-30 | -$73.99M 10-Q · filed 2014-11-13 | |
| 2013-12-31 | -$55.75M 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |